← All trials
NCT00637923
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2008
- Primary completion
- Apr 1, 2010
- Completion date
- Apr 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 112
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- RomarkLead sponsor
- Atlanta Gastroenterology AssociatesOverall official - principal investigator
- Yale UniversityOverall official - principal investigator
- Stanford UniversityOverall official - principal investigator
- Nashville Medical Research InstituteOverall official - principal investigator
- Cornell UniversityOverall official - principal investigator
- Florida Center for GastroenterologyOverall official - principal investigator
- Metropolitan ResearchOverall official - principal investigator
- Department of Veteran AffairsOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- RomarkStudy director
- St. Louis UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.